Patents by Inventor Bernard Thomas Golding

Bernard Thomas Golding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220106287
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: April 12, 2021
    Publication date: April 7, 2022
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Patent number: 11261171
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 1, 2022
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • Publication number: 20210276984
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: February 1, 2021
    Publication date: September 9, 2021
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Patent number: 10981898
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: April 20, 2021
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • Publication number: 20200247789
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: August 8, 2019
    Publication date: August 6, 2020
    Applicants: ASTEX THERAPEUCTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Publication number: 20200079761
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: August 8, 2019
    Publication date: March 12, 2020
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, lldiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mantyla NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Patent number: 10544132
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 28, 2020
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • Patent number: 10526311
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 7, 2020
    Assignees: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni Chessari, Steven Howard, Ildiko Maria Buck, Benjamin David Cons, Christopher Norbert Johnson, Rhian Sara Holvey, David Charles Rees, Jeffrey David St. Denis, Emiliano Tamanini, Bernard Thomas Golding, Ian Robert Hardcastle, Celine Florence Cano, Duncan Charles Miller, Martin Edward Mäntylä Noble, Roger John Griffin, James Daniel Osborne, Joanne Peach, Arwel Lewis, Kim Louise Hirst, Benjamin Paul Whittaker, David Wyn Watson, Dale Robert Mitchell
  • Patent number: 10414726
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Grant
    Filed: September 26, 2017
    Date of Patent: September 17, 2019
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Publication number: 20190055215
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: September 29, 2016
    Publication date: February 21, 2019
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, Ildiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST.DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Publication number: 20190016708
    Abstract: The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 17, 2019
    Applicants: ASTEX THERAPEUTICS LIMITED, CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Gianni CHESSARI, Steven HOWARD, IIdiko Maria BUCK, Benjamin David CONS, Christopher Norbert JOHNSON, Rhian Sara HOLVEY, David Charles REES, Jeffrey David ST. DENIS, Emiliano TAMANINI, Bernard Thomas GOLDING, Ian Robert HARDCASTLE, Celine Florence CANO, Duncan Charles MILLER, Sarah CULLY, Martin Edward Mäntylä NOBLE, Roger John GRIFFIN, James Daniel OSBORNE, Joanne PEACH, Arwel LEWIS, Kim Louise HIRST, Benjamin Paul WHITTAKER, David Wyn WATSON, Dale Robert MITCHELL
  • Publication number: 20180118684
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Application
    Filed: September 26, 2017
    Publication date: May 3, 2018
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas GOLDING, Christiane RIEDINGER, Roger John GRIFFIN, Ian Robert HARDCASTLE, Eric VALEUR, Anna Frances WATSON, Martin NOBLE
  • Publication number: 20160355478
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Application
    Filed: May 10, 2016
    Publication date: December 8, 2016
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas GOLDING, Christiane RIEDINGER, Roger John GRIFFIN, Ian Robert HARDCASTLE, Eric VALEUR, Anna Frances WATSON, Martin NOBLE
  • Patent number: 9358222
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: June 7, 2016
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Publication number: 20140194486
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Application
    Filed: November 20, 2013
    Publication date: July 10, 2014
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Bernard Thomas GOLDING, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Patent number: 8618158
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Grant
    Filed: June 25, 2009
    Date of Patent: December 31, 2013
    Assignee: Cancer Research Technology Limited
    Inventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcastle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Patent number: 8258175
    Abstract: A compound of formula or a prodrug and/or a pharmaceutically acceptable salt thereof, wherein X is O, N or S; R1 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroaralkyl; R2 is hydrogen, halo, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyalkyl substituted or unsubstituted alkylamine, alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; R3 is hydrogen, halo, hydroxy, substituted or unsubstituted alloy substituted or unsubstituted hydroxyalkyl, substituted or unsubstituted alkylamine alkoxy, substituted or unsubstituted aryl or heteroaryl, and substituted or unsubstituted aralkyl or heteroalkyl; and R4-R7, is used to represent groups R4, R5, R6 and R7 which are H, OH, alkyl, alkoxy, alkylamine, hydroxyalkyl, h
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: September 4, 2012
    Assignee: Cancer Research Technology Limited
    Inventors: Hendrika Maria Gerarda Willems, Per Kallblad, Ian Robert Hardcastle, Roger John Griffin, Bernard Thomas Golding, John Lunec, Martin E. M. Noble, David R. Newell, Alan H. Calvert
  • Publication number: 20110224274
    Abstract: A compound of formula (I) or a compound of formula (II) or pharmaceutically acceptable salts thereof, wherein R1-R7 and X are as defined in the description, and the use of these compounds in therapy, in particular in treating cancer or as an inhibitor of the interaction of the MDM2 protein with p53.
    Type: Application
    Filed: June 25, 2009
    Publication date: September 15, 2011
    Inventors: Bernard Thomas Golding, Christiane Riedinger, Roger John Griffin, Ian Robert Hardcasctle, Eric Valeur, Anna Frances Watson, Martin Noble
  • Publication number: 20110130386
    Abstract: A compound of formula (I) wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and RN1 and RN2 are selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms.
    Type: Application
    Filed: April 24, 2009
    Publication date: June 2, 2011
    Inventors: Mark Frigerio, Heather Mary Ellen Duggan, Marc Geoffrey Hummersone, Keith Allan Menear, Niall Morrison Barr Martin, Celine Cano, Roger John Griffin, Bernard Thomas Golding, Ian Robert Hardcastle
  • Patent number: 7732483
    Abstract: A compound of formula I: and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein: R1 and R2 are independently selected from hydrogen, an optionally substituted C1-7 alkyl group, C3-20 heterocyclyl group, or C5-20 aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; Q is —NH—C(?O)— or —O—; Y is an optionally substituted C1-5 alkylene group; X is selected from SR3 or NR4R5, wherein, R3, or R4 and R5 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl groups, or R4 and R5 may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; if Q is —O—, X is additionally selected from —C(?O)—NR6R7, wherein R6 and R7 are independently selected from hydrogen, optionally substituted C1-7 alkyl, C5-20 aryl, or C3-20 heterocyclyl gro
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: June 8, 2010
    Assignees: Kudos Pharmaceuticals Limited, Cancer Research Technology Limited
    Inventors: Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Keith Allan Menear, Marc Geoffrey Hummersone, Laurent Jean Martin Rigoreau, Roger John Griffin, Bernard Thomas Golding, David Richard Newell, Hilary Alan Calvert, Nicola Jane Curtin, Ian Robert Hardcastle, Kappusamy Saravanan